CDMOs have become essential infrastructure for the synthetic biology ecosystem, enabling startups and established companies to access production capacity without the enormous capital investment required to build dedicated manufacturing facilities. A typical biopharmaceutical manufacturing facility can cost $200 million to $1 billion to construct, a prohibitive investment for most synthetic biology startups. CDMOs amortize these capital costs across multiple clients, providing flexible access to fermentation, purification, and fill-finish capabilities at scales from clinical supply to commercial production.
The CDMO landscape for synthetic biology products spans several specialized segments. National Resilience was founded specifically to address biomanufacturing capacity challenges, building a network of advanced facilities for cell and gene therapy, nucleic acid, and protein production. Ajinomoto Bio-Pharma Services, Lonza, and Samsung Biologics offer large-scale fermentation and mammalian cell culture manufacturing. For non-pharmaceutical applications, CDMOs like Libragen and specialized contract manufacturers provide fermentation capacity for food ingredients, industrial enzymes, and specialty chemicals produced through precision fermentation.
The relationship between synthetic biology companies and CDMOs requires careful management of intellectual property, technology transfer, and quality systems. The process of transferring an engineered strain and fermentation process from a company's development laboratory to a CDMO's manufacturing facility is itself a significant undertaking, often requiring months of collaborative process optimization. Companies like Ginkgo Bioworks play a connecting role in the ecosystem, engineering strains that are then manufactured by CDMO partners. The maturation of the CDMO ecosystem for synthetic biology products is a critical enabler for the sector's growth, as manufacturing bottlenecks and costs have historically been among the most significant barriers to commercialization.